We got 15 minutes of information. Expecting perfection of completeness and complaining about not getting it is just childish. The ANAVEX slide package given is more than should have been expected. The results revealed are so uniformly supportive of the p2a AD trial results it is difficult to imagine that it could have been any better. I believe your conclusions are a good assessment. Thank you.
There is nothing revenue driving on the immediate horizon.
The SP going down was just good old fashioned sell the news. No cabal needed.
Great and predictable way to take profit and join again for the next round, but hopefully that opportunity will eventually fade with P3 trial readouts.
JJ good point. Makes me wonder how Eli Lilly’s results faired? Will they get a LB spot at next years prestigous CTAD conference......uhm NO because their Alzheimer’s drug crashed and burned while ours SUPPORTED our Alzheimer’s trial MOA. Most likely we will see them at one of the upcoming Parkinsons conferences.
Perhaps this Parkinsons release at an Alzheimer’s conference served more than one unforseen purpose. It allowed us to expose our limited great results in a different light highlighting/reinforcing our Alzheimer’s trial and the best (full analysis 3rd party peer reviewed) is yet to come. A really high end hors d’oeuvre if you will or “bonus”! Im sure Lilly is well aware of our findings and may now just be picking their jaw up off the ground!